SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-010555 to Aquestive Therapeutics, Inc. (AQST) (CIK 0001398733) (AQST)

Aquestive Therapeutics, Inc. (AQST) (CIK 0001398733)
Date: Sept. 25, 2023 · CIK: 0001398733 · Accession: 0000000000-23-010555

AI Filing Summary & Sentiment

File numbers found in text: 333-274609

Date
September 25, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Aquestive Therapeutics, Inc. (AQST) (CIK 0001398733)

Letter

United States securities and exchange commission logo September 25, 2023 Lori J. Braender Senior Vice President, General Counsel, Aquestive Therapeutics, Inc. 30 Technology Drive Warren, New Jersey 07059 Re:Aquestive Therapeutics, Inc. Registration Statement on Form S-3 Filed September 21, 2023 File No. 333-274609 Dear Lori J. Braender: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika N. Sheppard at (202) 551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anna Tomczyk, Esq

Show Raw Text
United States securities and exchange commission logo
September 25, 2023
Lori J. Braender
Senior Vice President, General Counsel,
Aquestive Therapeutics, Inc.
30 Technology Drive
Warren, New Jersey 07059
Re:Aquestive Therapeutics, Inc.
Registration Statement on Form S-3
Filed September 21, 2023
File No. 333-274609
Dear Lori J. Braender:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tamika N. Sheppard at (202) 551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Anna Tomczyk, Esq